ADMA Q1 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025

Earnings

ADMA Biologics delivered a quarter of sharp top-line growth but came in just shy of Wall Street's expectations, sending shares lower despite a year that has otherwise rewarded investors handsomely. The Boca Raton-based plasma therapeutics company pos… Read more ADMA Biologics delivered a quarter of sharp top-line growth but came in just shy of Wall Street's expectations, sending shares lower despite a year that has otherwise rewarded investors handsomely. The Boca Raton-based plasma therapeutics company posted Q1 2025 revenue of $114.80 million, up 40.2% year-over-year but trailing the $116.40 million consensus by 1.37%, while GAAP diluted EPS of $0.11 missed the $0.13 estimate by 15.38%. The shortfall was tied in part to a one-time impact from voluntary product withdrawals; on an adjusted basis, total revenue reached $118.64 million, reflecting roughly 45% year-over-year growth. Gross margin expanded meaningfully to 53.2% from 47.8% a year ago, driven by a richer mix of higher-margin immunoglobulin sales. Offsetting the near-term miss, management raised full-year 2025 revenue guidance to more than $500.00 million and set a 2026 target of $625.00 million or more, with a longer-term pre-2030 annual revenue goal lifted to $1.10 billion, supported by FDA approval of a yield enhancement process expected to boost finished immunoglobulin output by 20% from the same plasma volume.